Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.

about

A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer.Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.Antiangiogenic therapy in breast cancer.

P2860

Q35407573-4DFFCF0A-DF6E-45EF-ACE1-CDA56E1426BA Q37102447-498DF9F5-F25A-4683-96A8-D0D0BDDE75DD Q47111400-C7E0C647-0F1C-4730-9B63-1AA5E244968E

P2860

Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q36102859

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Influence of the American ODAC ...... for metastatic breast cancer.

@ast

Influence of the American ODAC ...... for metastatic breast cancer.

@en

type

Item

label

Influence of the American ODAC ...... for metastatic breast cancer.

@ast

Influence of the American ODAC ...... for metastatic breast cancer.

@en

prefLabel

Influence of the American ODAC ...... for metastatic breast cancer.

@ast

Influence of the American ODAC ...... for metastatic breast cancer.

@en

P1476

Influence of the American ODAC ...... e for metastatic breast cancer

@en

P2093

Christoph C Zielinski

http://www.w3.org/2001/XMLSchema#string

Gerhard Fülöp

http://www.w3.org/2001/XMLSchema#string

Guenther G Steger

http://www.w3.org/2001/XMLSchema#string

Harald Heinzl

http://www.w3.org/2001/XMLSchema#string

Richard Greil

http://www.w3.org/2001/XMLSchema#string

Rupert Bartsch

http://www.w3.org/2001/XMLSchema#string

P2860

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Angiogenic factors

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.

P304

e13-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2012-0115

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Matthias Preusser

Anna S Berghoff

P577

2012-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228088688

http://www.w3.org/2001/XMLSchema#string

P698

22744818

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

3399659

http://www.w3.org/2001/XMLSchema#string

Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.

about

P2860

P2860

Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932